Stephen K. Brannan, a director at Serina Therapeutics, Inc. (NASDAQ: SER), has acquired a stake in the company's equity, according to a filing submitted to the Securities and Exchange Commission. On July 7, 2026, Brannan purchased 1,000 shares of Serina Therapeutics common stock at a price of $2.03 per share. The total value of this transaction amounted to $2,029. Following this acquisition, Brannan directly holds 1,000 shares of Serina Therapeutics common stock.
The stock currently trades at $2.17, representing an increase of approximately 5% over the past week. Serina Therapeutics, Inc. is a pharmaceutical preparations company based in Huntsville, AL. The company carries a market cap of $32.5 million and receives a "weak" financial health rating from InvestingPro, which offers 9 additional ProTips and comprehensive metrics for investors evaluating the stock.
Analysts maintain bullish price targets ranging from $8 to $11. In other recent news, Serina Therapeutics has seen several noteworthy developments. BTIG has initiated coverage on Serina Therapeutics with a Buy rating, setting a price target of $8.00. This move reflects confidence in the company's drug delivery platform, which utilizes proprietary POZ-polymers. In addition, Serina Therapeutics announced a significant executive change, promoting Srini Tenjarla to the position of Chief Technology Officer. Dr. Tenjarla, previously Senior Vice President of CMC and Formulation, will now have an annual base salary of $425,000, effective retroactively from March 15, 2026. These updates were disclosed in the company's latest SEC filing, alongside changes to its corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Serina TherapeuticsFollowAnalyze SERIncluded in our AI-picked strategies·Review strategies2.205▲+0.2050(+10.25%)Real-time Data·12:17:47·USD1D1W1M6M1Y5YMaxCreated with Highcharts 11.4.818:0019:0009/0715:0016:001.81.922.1Analyze SERIs now the time to buy SER?ProPicks AI evaluates SER every month against thousands of alternatives using 100+ financial metrics.It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could SER be next—or is there a better opportunity in the same space?Don't wait to find out.July Sale - 60% Off InvestingPro